Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Soliton (SOLY) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Soliton (SOLY) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Thermo Fisher Scientific (TMO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued strength in Clear Aligner shipment volumes in Q2.
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The rest of businesses within Life-Science Solutions segment of Thermo Fisher (TMO) are likely to have registered strong quarterly growth led by genetic sciences and bio production businesses.
OrganiGram (OGI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its focus on building brand equity and product launches in the fiscal third quarter despite pandemic-hit business conditions.
Turtle Beach, Eventbrite, Thermo Fisher Scientific, UBS Group and Canadian Pacific Railway highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Turtle Beach, Eventbrite, Thermo Fisher Scientific, UBS Group and Canadian Pacific Railway highlighted as Zacks Bull and Bear of the Day
Medical Instruments Outlook Dull Amid Coronavirus Crisis
by Urmimala Biswas
Many sub domains within the medical instrument space are bearing the brunt of the coronavirus-led prolonged stay-at-home orders.
Time to Study Earnings: Global Week Ahead
by John Blank
"Bottoms-up" consensus expects earnings per share (EPS) to average $25.60 across Q2, down -6% from Q1, and close to a -40% drop in y/y terms. Guidance--if provided--becomes critical. So too will survival measures such as cash on hand.
Top Research Reports for Apple, Microsoft & TMobile
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Microsoft (MSFT) and TMobile US (TMUS).
Thermo Fisher Stock Rises on Solid Q2 Growth Expectation
by Zacks Equity Research
Thermo Fisher (TMO) provides encouraging Q2 guidance for organic growth.
Danaher Shares Gain 26% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Danaher (DHR), with 26% growth in shares in the past three months, benefits from healthy demand for its products and synergistic benefits from acquired assets despite the pandemic-led woes.
Pharmaceutical Wholesale to Aid Walgreens' (WBA) Q3 Earnings?
by Zacks Equity Research
Walgreen Boots' (WBA) international businesses in the third quarter is likely to have suffered a huge blow with international trade coming almost to a standstill.
Why Thermo Fisher (TMO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: Facebook, Thermo Fisher Scientific, McDonalds, NIKE and QUALCOMM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Thermo Fisher Scientific, McDonalds, NIKE and QUALCOMM
3 AI Healthcare Stocks to Ride Out the Coronavirus Resurgence
by Manaswita Ghosh Dutta
Efficient use of data by artificially intelligent applications has put into the spotlight their urgent need in the healthcare domain.
QIAGEN's (QGEN) Selloff Deal With Thermo Fisher Progresses
by Zacks Equity Research
QIAGEN's (QGEN) acquisition deal with Thermo Fisher receives approval from QIAGEN shareholders.
Top Stock Reports for Facebook, Thermo Fisher & McDonalds
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Thermo Fisher Scientific (TMO) and McDonalds (MCD).
Thermo Fisher Grows on Coronavirus Diagnostic Tests Amid Crisis
by Zacks Equity Research
Thermo Fisher (TMO) is optimistic about ramped up production for its COVID-19 diagnostic test to meet growing global demand.
The Zacks Analyst Blog Highlights: Procter & Gamble, Eli Lilly, Thermo Fisher Scientific, Costco Wholesale and Shopify
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Eli Lilly, Thermo Fisher Scientific, Costco Wholesale and Shopify
5 Stocks to Tap the Nanotechnology Market Boom
by Sreoshi Bera
Given the current scenario, researchers are focusing on nanotechnology as it may offer valuable solutions for COVID-19.
Top Analyst Reports for Procter & Gamble, Eli Lilly & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Eli Lilly (LLY) and Thermo Fisher Scientific (TMO).
Danaher's (DHR) Product Offerings to Aid Amid Pandemic Scares
by Zacks Equity Research
Danaher's (DHR) risks from pandemic-related uncertainties are evident from weak sales projections for the second quarter. Demand for acute care diagnostics' related products might aid results.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Thermo Fisher (TMO) Partners With CSL to Expand Pharma Arm
by Zacks Equity Research
Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.
Why Is Thermo Fisher (TMO) Up 4.8% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.